Non-Hodgkin Lymphoma Therapeutics

A Global Strategic Business Report

MCP13614

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

4623

EXECUTIVE POOL

5850

PRICE

833

EXPERT INPUTS

38

COMPANIES

123

DATA TABLES

192

PAGES

6

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (21534)

302

CXO

1219

VICE PRESIDENT

10631

DIRECTOR

7163

MANAGER

2219

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Non-Hodgkin Lymphoma Therapeutics Market to Reach US$19.9 Billion by 2030

The global market for Non-Hodgkin Lymphoma Therapeutics estimated at US$13.2 Billion in the year 2024, is expected to reach US$19.9 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the analysis period. Growth in the Targeted segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 6.6% CAGR

The Non-Hodgkin Lymphoma Therapeutics market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Non-Hodgkin Lymphoma Therapeutics Market - Key Trends & Drivers Summarized

What Are Non-Hodgkin Lymphoma Therapeutics and Why Are They Critical for Cancer Treatment?
Non-Hodgkin lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is part of the body’s immune system. Therapeutics for NHL include a range of treatments such as chemotherapy, targeted therapies, immunotherapies, radiation therapy, and stem cell transplants. These treatments aim to eliminate cancerous cells, slow disease progression, and improve patient survival rates. Targeted therapies like monoclonal antibodies, along with novel treatments such as CAR-T cell therapy, have revolutionized the treatment of NHL by offering more precise, less toxic treatment options compared to traditional chemotherapy.

The importance of NHL therapeutics lies in their ability to improve outcomes for patients with this complex and often aggressive cancer. NHL comprises a diverse group of cancers that vary in behavior and response to treatment, making personalized, targeted approaches essential. Recent advances in immunotherapy, targeted treatments, and precision medicine have significantly improved the prognosis for many patients, particularly those with difficult-to-treat forms of NHL. These therapies are critical for enhancing survival rates, reducing side effects, and improving quality of life for patients.

How Is the Non-Hodgkin Lymphoma Therapeutics Market Evolving?
The non-Hodgkin lymphoma therapeutics market is evolving with the rapid development of targeted and immunotherapeutic treatments. One of the key trends shaping the market is the growing adoption of monoclonal antibodies and other targeted therapies that specifically attack cancer cells without harming healthy tissue. Rituximab, for example, is a widely used monoclonal antibody that targets CD20 on the surface of B-cells, helping the immune system destroy cancerous cells. Newer therapies like CAR-T cell therapy, which modifies a patient’s T-cells to attack cancer cells more effectively, are also gaining traction as breakthroughs in NHL treatment.

Another important trend is the increasing use of combination therapies, which involve using multiple drugs or treatment modalities to improve outcomes. Combining targeted therapies with traditional chemotherapy or immunotherapy has shown promise in enhancing treatment efficacy and overcoming drug resistance. Additionally, the rise of precision medicine is enabling more personalized approaches to NHL treatment, where therapies are tailored to the specific genetic mutations and biomarkers of each patient’s cancer.

Which Types of NHL Are Driving the Demand for Therapeutics?
The demand for non-Hodgkin lymphoma therapeutics is being driven by the increasing incidence of aggressive forms of NHL, such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. DLBCL, the most common type of NHL, is an aggressive cancer that requires intensive treatment with chemotherapy, targeted therapy, and, in some cases, stem cell transplants. Follicular lymphoma, a slower-growing form of NHL, is also driving demand for therapies that can manage the disease over the long term and prevent progression.

Other subtypes of NHL, such as mantle cell lymphoma and T-cell lymphoma, are also contributing to the demand for new and more effective treatment options. These cancers often respond poorly to standard chemotherapy, highlighting the need for innovative therapies like CAR-T cell therapy, immunomodulatory drugs, and next-generation targeted therapies. The focus on treating relapsed and refractory cases of NHL, where the cancer returns after initial treatment, is further driving research and development in the field of oncology.

What Are the Key Growth Drivers in the Non-Hodgkin Lymphoma Therapeutics Market?
The growth in the non-Hodgkin lymphoma therapeutics market is driven by several factors, with the increasing incidence of NHL and advances in cancer treatment being primary drivers. As more patients are diagnosed with NHL, the demand for effective and targeted treatments is rising. Another key driver is the rapid development of immunotherapies and targeted therapies, which are transforming the treatment landscape by offering more personalized and less toxic treatment options.

The growing focus on treating relapsed or refractory NHL is also contributing to market growth, as these patients require more advanced treatments after standard therapies have failed. The expansion of clinical trials and research into novel therapies, such as CAR-T cell therapy and bispecific antibodies, is creating new opportunities for improving patient outcomes. Additionally, government initiatives and increased funding for cancer research are supporting the development of new therapies, further driving growth in the NHL therapeutics market. The rise of precision medicine and personalized treatment approaches is also enhancing the effectiveness of NHL therapies, leading to better survival rates and improved quality of life for patients.

SCOPE OF STUDY

The report analyzes the Non-Hodgkin Lymphoma Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Immunotherapy, Targeted, Other Therapies).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Bayer AG; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

Tariff Impact on Global Supply Chain Patterns

Global Economic Update

Non-Hodgkin Lymphoma Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 38 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Prevalence of Non-Hodgkin Lymphoma (NHL) Drives Demand for Advanced Therapeutic Options

Increasing Adoption of Targeted Therapies Expands Market for Personalized Non-Hodgkin Lymphoma Treatment

Growing Use of Immunotherapy in NHL Strengthens Demand for CAR-T Cell Therapy and Monoclonal Antibodies

Technological Advancements in Biomarker Testing Propel Growth in Precision Medicine for Non-Hodgkin Lymphoma

Rising Focus on Combination Therapies Expands Market for Multi-Modal Treatment Approaches in NHL

Increasing Use of Next-Generation Sequencing (NGS) for Mutation Detection Fuels Growth in Personalized NHL Treatments

Growing Adoption of Bispecific Antibodies in Non-Hodgkin Lymphoma Strengthens Market for Novel Immunotherapeutic Options

Emerging Focus on Minimal Residual Disease (MRD) Monitoring Expands Opportunities for Improved NHL Treatment Outcomes

Rising Demand for Innovative Drug Delivery Systems in NHL Therapeutics Fuels Market Growth in Targeted Treatment Solutions

Increasing Investment in R&D for Novel NHL Drugs Drives Innovation in New Treatment Modalities

Growing Use of Biosimilars in Non-Hodgkin Lymphoma Treatment Expands Market for Cost-Effective Therapeutic Solutions

Technological Advancements in Immuno-Oncology Expand Market for Innovative Non-Hodgkin Lymphoma Therapies

Rising Adoption of Radioimmunotherapy for Non-Hodgkin Lymphoma Expands Market for Targeted Radiation Treatments

4. GLOBAL MARKET PERSPECTIVE

World Non-Hodgkin Lymphoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Targeted by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Targeted by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Targeted by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

JAPAN

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

CHINA

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

EUROPE

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

FRANCE

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

GERMANY

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

UNITED KINGDOM

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Arma Pharma	%
Bayer AG	%
Biocad	%
Bristol-Myers Squibb Company	%
ENTEROME	%
Pfizer, Inc.	%
Xencor, Inc.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll